Atopix Therapeutics Appoints CMO
This article was originally published in Scrip
Atopix Therapeutics Limited, a UK-based biotechnology company developing medicines to treat atopic dermatitis and severe asthma, has appointed Dr Andrew Zambanini chief medical officer. Zambanini has 25 years of experience in clinical medicine and the pharmaceutical industry. He has previously held positions at GlaxoSmithKline plc, where from 2003 until 2010 he held a variety of roles of increasing seniority up to vice-president level; Takeda Global R&D; Novartis AG; Kyowa Hakko Kirin UK; ProStrakan; Gilead Sciences; and Circassia.
You may also be interested in...
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.